Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janusz Jaroszyński

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Frontiers in Pharmacology|October 30, 2023
Reimbursement decision-making system in Poland systematically compared to other countriesAneta Mela, Elżbieta Rdzanek, Janusz Jaroszyński, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 9, 2018
The direct and indirect costs of epilepsy in Poland estimates for 2014-2016 yearsAneta Mela, Anna Staniszewska, Witold Wrona, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 23, 2024
AOTMiT reimbursement recommendations compared to other HTA agenciesAneta Mela, Dorota Lis, Elżbieta Rdzanek, et al.
Annals of Agricultural and Environmental Medicine : AAEM|December 28, 2020
Prevalence and selected determinants of the risk of problem gambling among Polish secondary school studentsIwona Niewiadomska, Lech Panasiuk, Joanna Chwaszcz, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 21, 2024
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agencyAneta Mela, Andrzej Tysarowski, Elżbieta Rdzanek, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2022
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncologyAneta Mela, Elżbieta Rdzanek, Andrzej Tysarowski, et al.
Frontiers in Pharmacology|October 5, 2020
Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015-2017 YearsAneta Mela, Elżbieta Rdzanek, Łukasz A Poniatowski, et al.
Medycyna Pracy|May 22, 2019
[Cytostatic and cytotoxic waste - rules of conduct in Poland]Marzena Furtak-Niczyporuk, Janusz Jaroszyński, Aneta Mela, et al.
Neural Plasticity|April 3, 2019
Brain Functional Reserve in the Context of Neuroplasticity after StrokeJan Dąbrowski, Anna Czajka, Justyna Zielińska-Turek, et al.
Frontiers in Pharmacology|September 14, 2020
Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015-2018 YearsAneta Mela, Łukasz A Poniatowski, Bartłomiej Drop, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Pharmacology|October 30, 2023
Reimbursement decision-making system in Poland systematically compared to other countriesAneta Mela, Elżbieta Rdzanek, Janusz Jaroszyński, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 9, 2018
The direct and indirect costs of epilepsy in Poland estimates for 2014-2016 yearsAneta Mela, Anna Staniszewska, Witold Wrona, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 23, 2024
AOTMiT reimbursement recommendations compared to other HTA agenciesAneta Mela, Dorota Lis, Elżbieta Rdzanek, et al.
Annals of Agricultural and Environmental Medicine : AAEM|December 28, 2020
Prevalence and selected determinants of the risk of problem gambling among Polish secondary school studentsIwona Niewiadomska, Lech Panasiuk, Joanna Chwaszcz, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 21, 2024
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agencyAneta Mela, Andrzej Tysarowski, Elżbieta Rdzanek, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2022
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncologyAneta Mela, Elżbieta Rdzanek, Andrzej Tysarowski, et al.
Frontiers in Pharmacology|October 5, 2020
Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015-2017 YearsAneta Mela, Elżbieta Rdzanek, Łukasz A Poniatowski, et al.
Medycyna Pracy|May 22, 2019
[Cytostatic and cytotoxic waste - rules of conduct in Poland]Marzena Furtak-Niczyporuk, Janusz Jaroszyński, Aneta Mela, et al.
Neural Plasticity|April 3, 2019
Brain Functional Reserve in the Context of Neuroplasticity after StrokeJan Dąbrowski, Anna Czajka, Justyna Zielińska-Turek, et al.
Frontiers in Pharmacology|September 14, 2020
Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015-2018 YearsAneta Mela, Łukasz A Poniatowski, Bartłomiej Drop, et al.
Pageof 2